Catalysts
NVCR Stock Catalysts
Earnings · Growth Drivers · Events · AIQ Catalyst
NVCR
CatalystsStock Catalyst Board
Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.
Upcoming reporting date available for this company.
Momentum 65/100 and sentiment 60/100 before the next covered event.
Updated Sep 6, 2026 · Sentiment 36.85%
Earnings History And Surprises
See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.
Earnings Expectations And Results
Compare what analysts expected with what the company reported across recent quarters.
| Report date | Fiscal period | EPS estimate | EPS actual | EPS surprise | Revenue estimate | Revenue actual |
|---|---|---|---|---|---|---|
| Jul 23, 2026 | — | -$0.33 | -$0.13 | +60.8% | $172.44M | $183.58M |
| Apr 30, 2026 | — | -$0.51 | -$0.62 | -21.0% | $167.77M | $174.06M |
| Feb 26, 2026 | — | -$0.41 | -$0.22 | +46.3% | $174.4M | $174.35M |
| Oct 30, 2025 | — | -$0.42 | -$0.33 | +21.4% | $174.4M | $167.2M |
| Jul 24, 2025 | — | -$0.39 | -$0.36 | +7.7% | $158.81M | $158.81M |
| Apr 24, 2025 | — | -$0.47 | -$0.31 | +34.0% | $153.87M | $154.99M |
| Feb 27, 2025 | — | -$0.34 | -$0.61 | -79.4% | $147.57M | $161.27M |
| Oct 30, 2024 | — | -$0.34 | -$0.28 | +17.6% | $153.05M | $155.1M |
Analyst Forecast And Price Targets
Wall Street consensus, rating distribution, and the current 12-month target range.
Event Read
Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.
Current event setup
Next known earnings or reporting date.
Current analyst expectation for the upcoming report.
Current analyst expectation for the upcoming report.
News pressure around the setup.
Where event reaction would show up first.
Composite decision read before event confirmation.
Analyst context
News And Sentiment
Recent company coverage, scored where source sentiment is available.
Top Biotech Gainers: ADVB Soars Over 200% In A Week, NVCR, MEDP Report Q2 Results, AGMB In Focus
Today's top biotech gainers include Advanced Biomed, which led the rally with a gain of more than 200% over the past week. Novocure climbed following strong Q2 results and a revised full-year revenue outlook, while Medpace gained on solid quarterly performance and a positive outlook, among others.
Novocure (NVCR) Hits New High on Optimistic Outlook, FDA Approval Hopes
Novocure Ltd (NASDAQ:NVCR) soared to a new 52-week high on Thursday as investors positioned their portfolios amid a higher growth outlook for full-year 2026, and ahead of the expected premarket approval...
Related Links
NVCR Catalysts FAQ
What are the next catalysts for NVCR stock?
NVCR's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.
What upcoming events could move NVCR stock?
Upcoming events that could move NVCR include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.
How could NVCR's next earnings report affect the stock?
NVCR's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.
What could drive NVCR stock higher?
NVCR could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.
What events could hurt NVCR stock?
NVCR could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.